Gan & Lee Pharma teams with IDF and Wechat



China-based Gan & Lee Pharmaceuticals (603087.SH) unveiled a partnership with the International Diabetes Federation (IDF) and will provide support to the IDF on diabetes prevention and treatment worldwide. The deal means Gan & Lee Pharma will provide medical education in the IDF diabetes school, back IDF's official Wechat account launch, and have the opportunity to partake in World Diabetes Day and the Centennial of Insulin event among other campagns. No financial details were disclosed.

The IDF Diabetes Atlas indicates that there were 463 million adult (aged 20-79) diabetes sufferers in 2019, and that tally is expected to reach 700 million by 2045. In addition, 1 in every 2 diabetes cases went undiagnosed in 2019, necessitating the publicity and educational drive. Gan & Lee and IDF will focus on global diabetes publicity and promotion campaigns to improve the quality of life for patients.

Gan & Lee was the first domestic firm capable of manufacturing recombinant insulins in China. Its portfolio includes long-acting insulin glargine injection, quick-acting insulin lispro injection, quick-acting insulin aspart injection, protamine zinc recombinant insulin lispro injection (25R), and the recently approved insulin aspart 30 injection.

Reference:

Related news
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (01558.HK) announced that the market approval filing for its insulin aspart 30 injection has been accepted for review by the National Medical Products Administration.
China-based Gan & Lee Pharmaceuticals (603087.SH) announced market approval in China for insulin aspart 30, a treatment for type 1 or 2 diabetes.
China-based Gan & Lee Pharmaceuticals (603087.SH) announced premarket notification filing (510k) approval from the US FDA for its injection pen needle.
China-based Gan & Lee Pharmaceuticals is set to hold an initial public offering (IPO) of 40.2 million shares to the Shanghai Stock Exchange (SSE).
China-based Gan & Lee Pharmaceuticals was approved by the China Securities Regulatory Commission (CSRC) to hold an initial public offering (IPO) to the Shanghai Stock Exchange (SSE).
Recent news
Brazil’s Ministry of Health (MoH) last week signed a contract with local pharmaceutical company Precisa Medicamentos for the purchase of 20 million doses of Indian partner Bharat Biotech’s SARS-CoV-2 vaccine Covaxin, totalling BRL 1.6 billion (USD 288 million).
Argentina’s Ministry of Health (MoH) last week launched two direct drug purchases aimed at procuring contraceptives from Bayer.
Mexico-based pharmaceutical firm Genomma Lab last week released 2020 financials, reporting MXN 13.9 billion (USD 670 million) turnover after 9.1% year-on-year (YOY) growth, and flaunting minor negative impact of the COVID-19 pandemic.
  • 1614588392046
  • Argentina,Brazil,Colombia,Chile,Puerto Rico ,Costa Rica,Panama,Peru,Paraguay,Uruguay,Ecuador ,Bolivia ,Mexico,Guatemala,Honduras,El Salvador,Belize,Nicaragua
  • Company
Argentine pharmaceutical company Richmond last week signed a memorandum of understanding (MoU) with the Russian Direct Investment Fund (RDIF) for the local manufacturing of the latter’s SARS-CoV-2 vaccine Sputnik V, which was rolled out in the country in December last year.
China's Center for Drug Evaluation (CDE) website indicates that FutureGen Biopharma’s M108, a claudin 18.2 (CLDN18.2) targeted monoclonal antibody (mAb), has passed the clinical trial approval process and will be assessed in general advanced solid tumors.
German giant Bayer HealthCare entered into a memorandum of understanding with the China Alliance of Rare Diseases (CARD).
Beijing-based DaWei Biotechnology, a microfluidic technology driven molecular diagnostics specialist, struck a partnership with leading domestic in vitro diagnostics company Maccura Biotechnology Co., Ltd (300463.SZ) on next-generation molecular diagnostics technologies.
Analytics Snapshot